S&P/ASX 200 Index (ASX: XJO) shares are 0.5% lower at 8,706.8 points on Tuesday.

With earnings season over, brokers have updated their ratings and 12-month price targets on scores of ASX 200 shares.

Here are three with strong upside potential.

Life360 Inc (ASX: 360)

The Life360 share price is $20.88, up 6.9% today.

Over the past month, this ASX 200 tech share has fallen 15%.

Bell Potter renewed its buy rating on Life360 shares but shaved its price target down from $35 to $34.

This suggests a potential 62% upside ahead.

Analyst Chris Savage said:

The 2Q2026 key metrics of MAU growth, paying circle growth and adjusted EBITDA were all ahead of our forecasts…

The 2026 guidance for MAU growth, consolidated revenue and adjusted EBITDA were all unchanged…

We retain our BUY recommendation and note we expect the buyback to be more active this quarter after only modestly commencing last quarter.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $167, up 1% today and down 43% over 12 months. 

Pro Medicus shares began rebounding in February, ahead of the broader sector, but it’s been a topsy-turvy recovery.

The ASX 200 healthcare share almost doubled in value between late February and early July, then fell on profit-taking.

The Pro Medicus share price is up 5% since the broader sector pivoted on 3 June.

Morgans has an accumulate rating with a 12-month target of $230 on Pro Medicus shares.

This implies a potential 38% upside ahead.

The broker said: 

FY26 confirms PME is executing at an even higher level than the market gave it credit for.

EBIT margin of 74.9% and constant currency EBIT growth of 30.6% both beat expectations comfortably, with the FX-driven softness in headline revenue a currency story, not a demand or execution one.

Momentum remains broad-based, implementations are ahead of schedule, renewals are a clean sweep, and the pipeline is opening up in new segments rather than just deepening in existing ones.

Looking ahead, FY27 is shaping as a genuine standout year.

Ramelius Resources Ltd (ASX: RMS)

The Ramelius Resources share price is $3.66, down 2.5% today.

Over the past month, this ASX 200 gold share has fallen 0.4%.

Morgans has a buy rating on Ramelius Resources shares with a $4.74 target.

This implies a potential 30% upside ahead.

The broker said:

RMS is expected to release FY27 guidance and an updated outlook to FY30 in Sep-26, following execution of the EPC contract for the Mt Magnet mill expansion, providing greater clarity on project costs and timing. 

The post 3 ASX 200 shares tipped by experts to jump 30% to 62% appeared first on The Motley Fool Australia.

More reading

• CSL shares have surged over 25%. Do brokers see more upside?
• Turning 60? You could be leaving superannuation money on the table
• Here are the top 10 ASX 200 shares today
• Which ASX gold company is Morgans’ preferred mid cap buy?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The CSL Ltd (ASX: CSL) share price has staged an extraordinary recovery over the past few months.

After dropping to around $90 in June, the healthcare giant is trading at around $171.57 on Tuesday.

That is a huge change in a short period. But with the CSL share price still comfortably short of its highs, could there be another leg higher?

The easy gains may be behind us

When the CSL share price was trading around $90, I thought the valuation looked exceptionally cheap for a company with its global healthcare operations and long-term growth potential.

Investors were pricing in plenty of disappointment following weaker guidance, restructuring, and uncertainty around the earnings outlook.

Since then, the CSL share price has risen by more than 90%.

At $171.57, I certainly would not describe the stock as dirt cheap anymore.

According to consensus estimates, CSL is expected to generate earnings per share of $9.01 in FY27, rising to $9.51 in FY28 and $10.10 in FY29.

That means CSL shares are currently trading on a PE ratio of around 19 times forecast FY27 earnings.

I think that still represents decent value for money, but the investment case has changed.

From here, I expect CSL’s earnings growth to become much more important for the market than simply recovering from an unusually depressed valuation.

What would a $200 CSL share price mean?

A move from $171.57 to $200 would represent further upside of around 17%.

I do not think that looks unrealistic. At $200, CSL would trade at roughly 22 times forecast FY27 earnings.

Looking further ahead, that falls to around 20 times the FY29 earnings estimate.

For a global healthcare company with strong positions in plasma therapies and other specialised treatments, I think that valuation could be justified if CSL delivers on the earnings recovery currently expected.

What could push it higher?

CSL Behring remains particularly important to the outlook.

The business has opportunities to grow demand for its immunoglobulin and albumin therapies while improving profitability as plasma collection becomes more efficient.

Margin recovery would be encouraging because it could allow revenue growth to translate into stronger earnings growth.

There are also still challenges elsewhere in the group, including pressure within CSL Vifor. But if earnings rise towards the current FY28 and FY29 forecasts, I think investors could become increasingly comfortable paying a higher price for the shares.

Foolish takeaway

I think the CSL share price could reach $200, although the path looks quite different from the recovery out of June’s lows.

At $171.57, the shares are no longer obviously cheap. They are trading at around 19 times forecast FY27 earnings after almost doubling in value.

For the CSL share price to move another 17% higher, I think the company will need to show that its earnings recovery is genuinely taking hold.

If it can do that, $200 does not look like an unreasonable valuation to me.

The post Is the CSL share price heading to $200? appeared first on The Motley Fool Australia.

More reading

• CSL shares have surged over 25%. Do brokers see more upside?
• CSL shares just fell 5% after a strong rally. Is the recovery losing steam?
• What Warren Buffett can teach Australians about superannuation
• Higher or lower: Where are CSL shares going next?
• ASX healthcare shares are 39% higher since June. Are you missing out?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.5% to 8,702.6 points on Tuesday.

Here are some new ratings from the experts this week.

Echo IQ Ltd (ASX: EIQ)

The Echo IQ share price is steady at 49 cents today, and up 73% over 12 months. 

Morgans has a buy rating on this ASX tech share with a 12-month price target of $1.10.

The broker said: 

EIQ has received a Not Substantially Equivalent (NSE) determination on its initial EchoSolv HF 510(k), despite an extensively validated dataset generated in line with FDA guidance. The device cannot be marketed under this application as submitted, pushing back the biggest near-term catalyst and revenue driver. Decision is a setback, but the timing points to a fixable problem.

The determination landed day 264 of the FDA’s 270-day clock, leaving the agency no scope to seek further information and forcing a decision on what it had. Management confirms a single outstanding statistical point, not a safety or clinical issue, and says the letter invites resubmission.

We read this as a file closed on expiry rather than a technology rejected, and the 510(k) route stays open.

In any case, the regulatory and timing risks have increased, reflected in a valuation cut to A$1.10.

Warrants the negative market reaction but ultimately view the validity of the tool as intact, this reads as a setback in how the data was presented and assessed, not a failure of the underlying technology itself.

James Hardie Industries PLC (ASX: JHX)

The James Hardie share price is $39.58, up 1.2% today and up 31% over 12 months. 

James Bills from Shaw and Partners has a hold rating on this ASX 200 materials share. 

He said (courtesy The Bull): 

James Hardie remains a global leader in fibre cement building products and continues to benefit from strong brand recognition and market share gains, particularly in North America.

The company has delivered solid long term earnings growth through product innovation and operational efficiency.

However, housing activity remains sensitive to interest rate movements and broader economic conditions, creating some uncertainty around demand in the near term. Given its strong fundamentals and balanced valuation, a hold recommendation remains appropriate.

Woolworths Group Ltd (ASX: WOW)

The Woolworths share price is $39, up 0.6% today and up 39% over 12 months. 

Bills has a sell rating on this ASX 200 consumer staples share. 

He explained: 

The supermarket group has experienced a strong recovery in the past year, with the share price recently trading near the upper end of its historical range.

While the company remains high quality with a leading position in Australian food retailing, much of the recent improvement appears to be reflected in the WOW share price.

Earnings growth is expected to remain relatively steady rather than exceptional, limiting scope for further share price appreciation from current levels.

Following the recent rally, investors may consider taking profits before re-allocating capital to opportunities with stronger growth potential and a more attractive risk-reward profile.

The post Buy, hold, sell: Echo IQ, James Hardie, Woolworths shares appeared first on The Motley Fool Australia.

More reading

• Experts name CBA and these big-name ASX 200 shares as sells this week
• How to build a superannuation portfolio generating $50,000 a year
• 6 ASX shares downgraded by brokers this week
• Morgans says these ASX shares could return 48% to 95%
• Where to invest $5,000 into ASX dividend shares

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.